Organization and Liquidity (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Incorporation date	Dec. 31, 2003
Cash and cash equivalents	$ 386,027	$ 400
Working capital deficit	(4,616,658)
Accumulated deficit	(119,430,187)	(118,912,290)
Net cash used in operating activities	$ 1,133,005	$ 137,162
Working capital, description	We intend to pursue sources of working capital from non-dilutive funding channels to support the Company's operations that could include, but not be limited to, (1) up to $3.350 million from potential royalties from commercial sales of Excellagen® from certain geographic regions, including the United States; (2) Federal government sponsored research grants; (3) agreements and arrangements covering distributor and strategic partnerships and drug royalty agreements based on the commercial sale of Generx following the successful completion of the planned FDA-cleared, Phase 3 AFFIRM clinical study and FDA registration in the U.S., and additional registrations to market and sell Generx in other countries internationally.
Angionetics [Member]
Equity-based investment ownership percentage	85.00%